There isn’t a single expiration date for trametinib. Patent expiry depends on:
- which patent family you’re looking at (compound/molecule patent vs. salts, formulations, or method-of-use patents vs. combination-use patents),
- and the jurisdiction (US, Europe, Japan, etc.), since each country has its own term rules and extensions.
In short, the main “compound” patent for trametinib (GSK’s trametinib, aka GSK‑1120212) will have a term of roughly 20 years from the earliest filing date, plus any US Patent Term Adjustment (PTA) or other extensions, and EU data/protection rules can add additional exclusivity time even after the patent lapses. Use of regulatory exclusivities (e.g., data protection in the EU or NCE exclusivity in the US) can also affect when a generic could enter.
If you want a precise answer, tell me:
- the jurisdiction(s) you care about (e.g., US, EU, Japan, etc.),
- whether you mean the primary compound patent, a salt/formulation patent, method-of-use, or a combination/use patent,
or I can help you look up the current status for those specific patent families in the jurisdictions you specify. Note: for the latest and exact dates, consulting patent databases (USPTO Patents Center or PatFT, Espacenet, Google Patents, WIPO Patentscope) or a patent attorney is recommended.